

Medtech / Biotech / Pharma

The 7th Prix Galien Medstartup Nominees are...

September 2019 --- The Galien Foundation and Business France are pleased to announce the nominees of the seventh Galien Medstartup Awards. 9 partnerships between French and American entities were nominated by a prestigious jury¹. 3 projects will then be awarded in New York on October 24th. The Awards ceremony is a celebration of innovation as well as scientific excellence and an opportunity to highlight the partnership opportunities between France and the United States in the fields of medical and pharmaceutical innovations. The French companies will also have the opportunity to meet with US stakeholders and investors to discuss the development of new partnerships.

¹Chaired by Bernard POUSSOT - Director, Roche Holding, Former President & CEO, WYETH, the jury of the Galien Medstartup Awards 2019 is composed of the most respected pharma industry leaders: Roch DOLIVEUX -Honorary CEO, UCB ; Mikael DOLSTEN - Global R&D President, Pfizer ; Jean-Pierre GARNIER – Former CEO, GSK ; Franz HUMER - Former CEO, Roche ; François MAISONROUGE - Senior Managing Director, Evercore Partners Paul STOFFELS - Chief Scientific Officer, Johnson and Johnson ; Elias ZERHOUNI – Former Global R&D President, Sanofi

“We are very proud of our partnership with Business France, explains Bruno Cohen, Chairman of the Galien Foundation. The Galien Medstartup program and awards are a perfect illustration of the long and mutually beneficial collaboration between France and the USA, always leading to breakthrough innovations.”

“Thanks to the Galien Foundation, we have been able to bootstrap some of the most innovative biotech startups and offer them partnerships critical to their success and rapid development, says Arnaud Leretour managing Director at Business France North America. The United States represents close to a quarter of foreign investments in the French pharmaceutical sector and 40% of the medical one. The Prix Galien Medstart’Up is a great opportunity to highlight this existing and very strong relationship and we are thrilled to work with the Galien Foundation every year to introduce the best of French biotech innovation to the American Pharmaceutical industry.”

MEDSTARTUP AWARDS NOMINEES 2019

BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY



Biomunex signed a licensing agreement with Sanofi for the generation and development of bi-specific and multi-specific antibodies.

BEST COLLABORATION IN THE MEDTECH OR DIGITAL SECTOR



DTA Medical collaborated with Tufts University to develop a medical device allowing constant monitoring of wound healing critical factors.

BEST COLLABORATION DEDICATED TO THE DEVELOPING OR UNDERSERVED POPULATIONS WORLDWIDE



Lysogene collaborated with Sarepta to develop a drug candidate in the treatment of MPSIIIA with gene therapy.



Eukarys collaborated with the **University of Alberta** to develop C3P3 technology and its applications in biologic manufacturing.

Novadiscovery and **BBN Cardio Therapeutics** are collaborating to build an *in silico* model of atherosclerosis and establish a proof of concept of efficacy before *in vivo* clinical trials.

Praesens foundation collaborated with the **Pasteur Institute** and **Twist Bioscience** in the development of an integrated solution for better preparedness and faster response to outbreaks and epidemics in high-risks areas.



NHTherAguix collaborated with the **Dana-Farber** and **Brigham and Women's Hospitals** on preclinical subjects first and are now moving on to a clinical trial on application of nanotechnologies to radiotherapeutic oncology in deep lung cancer and pancreatic cancer.



UroMems collaborated with the **Mayo Clinic** to develop a pivot study for a medical device to treat stress urinary incontinence.



Spring Vision collaborated with the **Foundation Fighting Blindness** to develop and launch a breakthrough disease-modifier gene therapy treatment for Retinitis Pigmentosa.

About Business France:

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France.

It promotes France's companies, business image and nationwide attractiveness as an investment location, and runs the "VIE" international internship program.

Founded on January 1, 2015 through a merger between UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. www.businessfrance.fr

About the Galien Foundation:

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org